Pharma Faces More Probes On Generic Price Hikes in UK

As Concordia finds itself in the dock again, this time over its pricing of the essential thyroid treatment liothyronine, the UK's Competition and Markets Authority has recently opened four new investigations into "suspected abuse of dominance" concerning generics.

Bills
The UK competition watchdog is keeping a close eye on drug prices • Source: Shutterstock

A number of pharmaceutical companies can shortly expect some difficult conversations with the UK's competition watchdog, which is pursuing more investigations into over-charging for drugs after Canada's Concordia International Corp. again found itself in the spotlight for price hikes on an essential thyroid treatment.

The Competition and Markets Authority (CMA) has provisionally found that Concordia "abused its dominant position to overcharge the NHS by...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legal & IP

More from Pink Sheet